NCT04869982View on ClinicalTrials.gov

Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

PHASE4CompletedINTERVENTIONAL
Enrollment

6,138

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

April 20, 2023

Study Completion Date

April 20, 2023

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

RZV

2 doses of RZV in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm

DRUG

Placebo

2 doses of placebo in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm

Trial Locations (6)

200001

GSK Investigational Site, Shanghai

200051

GSK Investigational Site, Shanghai

200090

GSK Investigational Site, Shanghai

201620

GSK Investigational Site, Shanghai

222100

GSK Investigational Site, Lianyungang

223005

GSK Investigational Site, Huaian

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY